IAG’s Imaging Expert Team Discuss Successful Oncology Clinical Trials and the Impact of Novel Technologies
Join Dr. Diana Dupont-Roettger, Chief Scientific Alliance Officer and Sebastien Jacques, Senior Project Manager for Oncology during a live webinar to discuss the role of new technology and imaging that support successful oncology clinical trial delivery.
Replay link is available here
Request password: firstname.lastname@example.org or email@example.com
About the Webinar:
IAG’s imaging experts will share their experience in designing and delivering oncology clinical trials, that use quantitative imaging alongside standard radiographic response criteria, such as RECIST 1.1, iRECIST, RANO, Lugano.
The individual steps that are crucial for successful imaging data management that complies with latest regulatory requests will be outlined and discussed.
In addition, the team will highlight how the use of DYNAMIKA, IAG’s cloud based trial infrastructure, adds efficiencies and cost savings.
Key discussion points:
- Quality, Integrity and Security of data in a cloud-based trial infrastructure
- Speed of the processes and ability to make decisions fast
- Change between high level trial overview and details
- Real time availability of data
- Transparency of stakeholders’ performance
- Integration of Advanced Imaging
About Sebastien Jaques, MSc, PMP:
Experienced Project Manager with a 12+ years of history of working in the pharmaceuticals industry. Skilled in Management, Software Engineering and Information Technology, as well operational planning and oversight, planning of risks, resource, time, budget and effectively managing the project and the project team from concept to database lock.
About Dr. Diana Dupont-Roettger:
Diana is a Medical Computer Scientist by background with strong experience in novel imaging technologies and imaging markers as well as their role for biotech and pharma. She is an expert in scientific imaging clinical trial design and advises biotech and pharma on the strategic use of advanced imaging to evaluate mechanism of action, enable precision medicine and accelerate drug development in immuno-oncology and neuro-oncology indications. Diana is actively working with biotech, pharma and investment funds helping to bridge the gap between academic research, business objectives and finances.
IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com